James S Hardwick
Overview
Explore the profile of James S Hardwick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
1159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maresca K, Chen J, Mathur D, Giddabasappa A, Root A, Narula J, et al.
Mol Imaging Biol
. 2021 Jun;
23(6):941-951.
PMID: 34143379
Purpose: A sensitive and specific imaging biomarker to monitor immune activation and quantify pharmacodynamic responses would be useful for development of immunomodulating anti-cancer agents. PF-07062119 is a T cell engaging...
2.
Cao J, Zhu Z, Wang H, Nichols T, Lui G, Deng S, et al.
Oncogene
. 2019 Feb;
38(21):4125-4141.
PMID: 30700828
The CDK4/6 inhibitor palbociclib reduces tumor growth by decreasing retinoblastoma (RB) protein phosphorylation and inducing cell cycle arrest at the G1/S phase transition. Palbociclib in combination with anti-hormonal therapy brings...
3.
Paulson K, Tegeder A, Willmes C, Iyer J, Afanasiev O, Schrama D, et al.
Cancer Immunol Res
. 2014 Aug;
2(11):1071-9.
PMID: 25116754
Merkel cell carcinoma (MCC) is an aggressive, polyomavirus-associated skin cancer. Robust cellular immune responses are associated with excellent outcomes in patients with MCC, but these responses are typically absent. We...
4.
Weber D, Graef T, Hussein M, Sobecks R, Schiller G, Lupinacci L, et al.
Clin Lymphoma Myeloma Leuk
. 2012 Oct;
12(5):319-24.
PMID: 23040438
Unlabelled: Preclinical studies have shown that targeted combination therapy consisting of vorinostat and bortezomib has antitumor activity in multiple myeloma (MM). We examined this drug combination in advanced relapsing and/or...
5.
Dummer R, Beyer M, Hymes K, Epping M, Bernards R, Steinhoff M, et al.
Leuk Lymphoma
. 2012 Jan;
53(8):1501-8.
PMID: 22239668
The retinoid X receptor (RXR)-agonist bexarotene and the histone deacetylase inhibitor (HDACI) vorinostat are each established monotherapies for cutaneous T-cell lymphomas (CTCLs). We investigated the combination of HDACI and retinoic...
6.
Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodriguez-Braun E, et al.
Clin Cancer Res
. 2011 Aug;
17(19):6304-12.
PMID: 21810918
Purpose: Insulin-like growth factor-1 receptor (IGF-1R) mediates cellular processes in cancer and has been proposed as a therapeutic target. Dalotuzumab (MK-0646) is a humanized IgG1 monoclonal antibody that binds to...
7.
Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice J, et al.
J Clin Oncol
. 2011 Mar;
29(11):1495-501.
PMID: 21383291
Purpose: Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced nausea/vomiting (CINV), particularly during the delayed phase (DP; 25 to 120...
8.
Peters C, Rees J, Hardwick R, Hardwick J, Vowler S, Ong C, et al.
Gastroenterology
. 2010 Jul;
139(6):1995-2004.e15.
PMID: 20621683
Background & Aims: The incidence of esophageal and junctional adenocarcinoma has increased 6-fold in the past 30 years and 5-year survival remains approximately 20%. Current staging is limited in its...
9.
Saadi A, Shannon N, Lao-Sirieix P, ODonovan M, Walker E, Clemons N, et al.
Proc Natl Acad Sci U S A
. 2010 Jan;
107(5):2177-82.
PMID: 20080664
The stromal compartment is increasingly recognized to play a role in cancer. However, its role in the transition from preinvasive to invasive disease is unknown. Most gastrointestinal tumors have clearly...
10.
Fujiwara Y, Yamamoto N, Yamada Y, Yamada K, Otsuki T, Kanazu S, et al.
Cancer Sci
. 2009 Jul;
100(9):1728-34.
PMID: 19575752
Vorinostat (suberoylanilide hydroxamic acid), a potent, oral histone deacetylase inhibitor, has demonstrated clinical activity in non-Japanese patients with various hematological and solid tumors. We sought to determine the maximum tolerated...